Overview

A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid Tumors

Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
A multicentre, 2-part study to assess the safety and tolerability of once daily oral doses of AZD2171 when administered with various anticancer regimens (part A) and to confirm the tolerability of its combination with FOLFOX (part B).
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Treatments:
Cediranib
Cetuximab
Docetaxel
Fluorouracil
Irinotecan
Leucovorin
Oxaliplatin
Pemetrexed